TALIS BIOMEDICAL CORP (TLIS) Stock Analyst Earnings Estimates
NASDAQ:TLIS - Nasdaq - US87424L2079 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|
| Revenue YoY % growth | 8.193M -25.10% | 4.812M -41.27% | 2.134M -55.65% | -100.00% | 13.26M | |
| EBITDA YoY % growth | -190.238M -110.39% | -106.309M 44.12% | -63.245M 40.51% | -80.58M -27.41% | -68.34M 15.19% | |
| EBIT YoY % growth | -191.816M -110.36% | -115.139M 39.97% | -64.015M 44.40% | -72.42M -13.13% | -70.125M 3.17% | |
| Operating Margin | -2,341.22% | -2,392.75% | -2,999.77% | N/A | -528.85% | |
| EPS YoY % growth | -27.51 73.20% | -63.60 -131.19% | N/A 48.33% | -23.79 27.62% | -28.34 -19.13% |
All data in USD
| Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -5.16 40.13% | -5.91 13.32% | -7.13 -6.23% | -7.17 -18.95% | -7.48 -44.86% | -6.56 -11.05% |
| Revenue Q2Q % growth | -100.00% | -100.00% | -100.00% | 408K | 12.852M | |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -10.812M 23.70% | -12.342M 14.62% | -14.79M -62.22% | -14.892M -73.61% | -15.504M -43.40% | -13.872M -12.40% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2024 Q2Q % growth | 32.21% | -6.71 | % | |
| Q4 2023 Q2Q % growth | 54.58% | -6.81 | % | |
| Q3 2023 Q2Q % growth | -8.62 41.36% | -7.52 | -1.10 | -14.67% |
| Q2 2023 Q2Q % growth | 95.32% | -0.71 | % | |
| Q1 2023 Q2Q % growth | -9.90 47.20% | -11.17 | 1.27 | 11.36% |
| Q4 2022 Q2Q % growth | -15.00 20.63% | -10.48 | -4.52 | -43.12% |
| Q3 2022 Q2Q % growth | -14.70 -886.58% | -11.93 | -2.77 | -23.18% |
| Q2 2022 Q2Q % growth | -15.15 -503.59% | -12.32 | -2.83 | -23.01% |
| Q1 2022 Q2Q % growth | -18.75 -306.72% | -18.05 | -0.70 | -3.86% |
| Q4 2021 Q2Q % growth | -18.90 9.31% | -19.63 | 0.73 | 3.74% |
| Q3 2021 Q2Q % growth | -1.49 | -1.43 | -0.06 | -4.34% |
| Q2 2021 Q2Q % growth | -2.51 | -0.93 | -1.58 | -169.67% |
| Q1 2021 Q2Q % growth | -4.61 | -0.77 | -3.85 | -502.61% |
| Q4 2020 Q2Q % growth | -20.84 | -0.80 | -20.04 | -2,502.72% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2024 Q2Q % growth | 73K -93.25% | 73K | % | |
| Q4 2023 Q2Q % growth | 195K -24.12% | 102K | 93K | 91.18% |
| Q3 2023 Q2Q % growth | 140K -82.41% | 102K | 38K | 37.25% |
| Q2 2023 Q2Q % growth | 581K 1.57% | 51K | 530K | 1,039.22% |
| Q1 2023 Q2Q % growth | 1.081M -66.08% | 255K | 826K | 323.92% |
| Q4 2022 Q2Q % growth | 257K -70.05% | 816K | -559K | -68.50% |
| Q3 2022 Q2Q % growth | 796K 265.14% | 312.803K | 483.197K | 154.47% |
| Q2 2022 Q2Q % growth | 572K 388.89% | 714K | -142K | -19.89% |
| Q1 2022 Q2Q % growth | 3.187M -54.47% | 663K | 2.524M | 380.69% |
| Q4 2021 Q2Q % growth | 858K 268.24% | 1.36M | -502K | -36.91% |
| Q3 2021 Q2Q % growth | 218K -97.70% | 1.489M | -1.271M | -85.36% |
| Q2 2021 Q2Q % growth | 117K -85.73% | 117K | % | |
| Q1 2021 Q2Q % growth | 7M 1,654.39% | 5.75M | 1.25M | 21.74% |
| Q4 2020 Q2Q % growth | 233K -84.54% | 1.937M | -1.704M | -87.97% |
| Q3 2020 Q2Q % growth | 9.486M 284.05% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | 0% |
| Revenue | N/A | N/A | N/A | N/A |